Across TCGA pan-cancer cohorts, GPX5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GPX5 data layer compared with 16 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher GPX5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPX5 expression acts as an unfavorable survival marker.
READ and GBM are the cancer types where GPX5 Mutation most reproducibly stratifies survival.